Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 192 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CD Clear all
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

NCT00004900
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 4, 2026, 12:12 PM EDT
Recruiting Phase 3 Interventional

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 19 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
11
States / cities
San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 4, 2026, 12:12 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

NCT03559517
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lancaster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 4, 2026, 12:12 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

NCT03627091
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ontamalimab, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
73
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Not applicable Interventional

Partial-enteral Nutrition Protocol for Crohn's Disease

NCT07113431
View directory record Official record
Conditions
Crohn's Disease(CD)
Interventions
IBD-AID diet combined with Kate Farms Peptide 1.5, IBD-AID diet
Dietary Supplement · Other
Lead sponsor
Kate Farms Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 4, 2026, 12:12 PM EDT
Active, not recruiting Phase 1 Interventional

EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma

NCT01192464
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
autologous CAR.CD30 EBV specific-CTLs
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2033
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

NCT04380142
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
70
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 4, 2026, 12:12 PM EDT
Not yet recruiting Phase 4 Interventional

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

NCT07059130
View directory record Official record
Conditions
Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
Interventions
Mirikizumab
Biological
Lead sponsor
Rubix LS
Industry
Eligibility
60 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 4, 2026, 12:12 PM EDT
Recruiting Phase 4 Interventional

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

NCT06997965
View directory record Official record
Conditions
Crohn Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

NCT00586599
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
measurement of inflammatory markers
Other
Lead sponsor
Indiana University
Other
Eligibility
7 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 4, 2026, 12:12 PM EDT
Recruiting Phase 3 Interventional

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06405087
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab SC, No Intervention
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Mid-life Women: Preventing Unintended Pregnancy and STIs

NCT02330133
View directory record Official record
Conditions
Reproductive Health
Interventions
Women's Reproductive Health, Online sexual health content
Behavioral
Lead sponsor
Oregon Center for Applied Science, Inc.
Industry
Eligibility
25 Years to 55 Years · Female only
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Not applicable Interventional Results available

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

NCT03241368
View directory record Official record
Conditions
Crohn Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 4, 2026, 12:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420
View directory record Official record
Conditions
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
Interventions
ALPCO Calprotectin CLIA
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
22 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salem, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 4, 2026, 12:12 PM EDT
Completed No phase listed Observational

Precision Opioid Care After Cesarean Delivery (PRECISE-CD)

NCT05280743
View directory record Official record
Conditions
Cesarean Section Complications, Opioid Use
Interventions
Oxycodone
Drug
Lead sponsor
Grace Lim, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
341 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 4, 2026, 12:12 PM EDT
Active, not recruiting No phase listed Observational

Response Assessment in SB CD

NCT03646708
View directory record Official record
Conditions
Small Bowel Crohn's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fecal Microbiota Transplantation in Pediatric Patients

NCT02108821
View directory record Official record
Conditions
Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 22 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 4, 2026, 12:12 PM EDT
Recruiting No phase listed Observational

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

NCT07198113
View directory record Official record
Conditions
Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 18 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

NCT00763555
View directory record Official record
Conditions
Psoriasis
Interventions
CD 2027, Calcitriol Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Fridley, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Phase 2 Interventional

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

NCT00101946
View directory record Official record
Conditions
Crohn's Disease
Interventions
683699
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Garden Grove, California • Roseville, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 4, 2026, 12:12 PM EDT
Terminated Phase 3 Interventional Results available

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

NCT01190839
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab, Placebo
Biological · Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
62
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacodynamic Study of CD-NP

NCT00482937
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
CD-NP
Drug
Lead sponsor
Nile Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2007 · Synced Sep 4, 2026, 12:12 PM EDT
Completed Not applicable Interventional Results available

Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer

NCT00450424
View directory record Official record
Conditions
Colorectal Cancer, Hereditary Non-polyposis Colon Cancer
Interventions
counseling intervention, CD-ROM intervention
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
21 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Newark, Delaware • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 4, 2026, 12:12 PM EDT